SharesGrow 7-Criteria Score
All 7 criteria scored · valuation-related highlighted on this page
Kiromic BioPharma, Inc. (KRBP) .
Criteria proven by this page:
- VALUE (0/100, Fail) — the composite valuation score falls below the 60/100 threshold required to pass.
Overall SharesGrow Score: 10/100 with 0/7 criteria passed.
SharesGrow 7-Criteria Score
✗
HEALTH
0/100
Debt-to-Equity & liquidity
→ Health
Valuation Snapshot — KRBP
Valuation Multiples
P/E (TTM)0.0
Forward P/EN/A
PEG RatioN/A
Forward PEGN/A
P/B Ratio0.00
P/S Ratio0.00
EV/EBITDA0.0
Per Share Data
EPS (TTM)$-1.03
Book Value / Share$0.00
Revenue / Share$0.00
FCF / Share$0.00
Yields & Fair Value
Earnings YieldN/A
Dividend Yield0.00%
P/E Ratio & Earnings Yield
Earnings Per Share (EPS) History
| Year |
EPS (Diluted) |
Revenue |
Net Income |
Net Margin |
| 2018 |
$-32.40 |
$0.00 |
$-3.82M |
- |
| 2019 |
$-29.00 |
$0.00 |
$-3.75M |
- |
| 2020 |
$-79.08 |
$0.00 |
$-19.2M |
- |
| 2021 |
$-67.40 |
$0.00 |
$-25.65M |
- |
| 2022 |
$-70.12 |
$0.00 |
$-38.18M |
- |
| 2023 |
$-21.41 |
$0.00 |
$-21.29M |
- |
| 2024 |
$-1.03 |
$0.00 |
$-26.9M |
- |
